Xenon Pharmaceuticals (XENE) Current Assets (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Current Assets of $1.1 billion for Q1 2026, up 95.68% year-over-year from $565.5 million in Q1 2025, and up 97.38% quarter-over-quarter from $560.6 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Current Assets (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Current Assets for 14 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 95.68% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 95.68% YoY), while the FY2025 annual figure was $560.6 million, down 11.75% from the prior year.
- Current Assets grew to $1.1 billion in Q1 2026 per XENE's latest filing, from $560.6 million in the prior quarter.
- Across five years, Current Assets topped out at $1.1 billion in Q1 2026 and bottomed at $480.1 million in Q3 2025.
- Historically, Current Assets has averaged $634.5 million across 5 years, with a median of $600.3 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets jumped 197.95% — and 2023, when it slumped 31.48%.
- Xenon Pharmaceuticals' Current Assets stood at $600.3 million in 2022, then advanced by 7.44% to $645.0 million in 2023, then dropped by 1.5% to $635.3 million in 2024, then declined by 11.75% to $560.6 million in 2025, then jumped by 97.38% to $1.1 billion in 2026.
- Business Quant data shows XENE's Current Assets at $1.1 billion in Q1 2026, $560.6 million in Q4 2025, and $480.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 945.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 945.87 Mn |
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 560.65 Mn |
| Sep 30, 2025 | 480.14 Mn |
| Jun 30, 2025 | 500.25 Mn |
| Mar 31, 2025 | 565.54 Mn |
| Dec 31, 2024 | 635.26 Mn |
| Sep 30, 2024 | 659.64 Mn |
| Jun 30, 2024 | 728.09 Mn |
| Mar 31, 2024 | 707.20 Mn |
| Dec 31, 2023 | 644.96 Mn |
| Sep 30, 2023 | 531.01 Mn |
| Jun 30, 2023 | 544.62 Mn |
| Mar 31, 2023 | 533.35 Mn |
| Dec 31, 2022 | 600.30 Mn |
| Sep 30, 2022 | 649.18 Mn |
| Jun 30, 2022 | 794.80 Mn |
| Mar 31, 2022 | 545.62 Mn |
| Dec 31, 2021 | 559.02 Mn |
| Sep 30, 2021 | 256.31 Mn |